GH · Guardant Health Inc
Price
Snapshot
50 fields · last close| Market Cap | $22.26B |
| P/E | — |
| Float | 128.0M |
| Beta | 1.70 |
| Volatility | 42.6% |
| Exchange | NASDAQ |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | High |
| Clavix score | 66.2 |
| Price | 156.68 |
| Change | −1.21% |
| Prev Close | 158.60 |
| Open | 160.78 |
| Day Low | 159.00 |
| Day High | 168.86 |
| Avg Vol | 2 |
| Avg $ Vol | $301.9M |
| 52W High | 191.05 |
| 52W Low | 61.00 |
| 52W Pos | 73.6% |
| From High | −17.99% |
| From Low | +156.86% |
| Max DD 1Y | −32.98% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −9.42% |
| SMA 50 | −6.77% |
| SMA 200 | +23.40% |
| RSI (14) | 46.1 |
| Vol 30D | 46.4% |
| Vol 90D | 50.3% |
| 1Y Range | 61–191 |
| Daily bars | 535 |
| Perf Week | +0.19% |
| Perf Month | −5.16% |
| Perf Quarter | +6.42% |
| Perf Half Y | +93.56% |
| Perf Year | +165.15% |
| Perf YTD | +54.00% |
| Prev Day | −1.21% |
| Clavix | C+ |
| Debt / Eq | 7.18 |
| Curr Ratio | 4.84 |
| Int Cover | -0.8× |
| FCF Margin | −23.7% |
| Rev Growth | +32.9% |
| Profit | Unprofitable |
| Leverage | Very High |
| Sector rank | 46 / 49 |
Clavix risk grade
regraded every trading dayGH grades C+, 66.2 of 100. Steadiest on News Sentiment (66), most exposed on Price Stability (50, mixed). 1 of the 4 weighted dimensions sit above the Health Care median. Ranks 46 of 49 in Health Care by Clavix score.
How rough the ride is
| GH | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.70 | 0.84 |
| Volatilityannualized | 42.6% | 21.1% |
| Max drawdown, past yearworst peak-to-trough fall | −33.0% | — |
| Typical daily movemedian absolute daily change | 1.79% | — |
| Days beyond ±3%of the last 252 sessions | 75 (30%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| GH | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.70 | 0.84 |
| Macro sensitivityrate, dollar and credit exposure bucket | High | Moderate 53% of 49 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| GH | |
|---|---|
| 1 week | +0.2% |
| 1 month | −5.2% |
| Year to date | +54.0% |
| 1 year | +165.2% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| GH | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 24 Aug |
| Average score0 most bearish, 100 most bullish | 56 |
| Bullish · bearisharticles above 60 · below 40 | 19 · 11 |
| Directionarticles whose tone is improving vs worsening | 19 ↑ 11 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 49 Health Care names Clavix covers; the tick is the sector median.
Growth
| GH | |
|---|---|
| Revenue growthyear over year | +32.9% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openGuardant Health announced that it and research collaborators presented new data at the American College of Gastroenterology 2026 Annual Meeting showing its Shield blood test was projected, in a modeling study of people aged 45 to 75 over a lifetime, to increase colorectal cancer screening and follow-up colonoscopy adherence compared to stool-based tests.
Guardant Health announced that its Guardant360 CDx blood test has received CE-marking in Europe as a companion diagnostic to identify advanced breast cancer patients who may benefit from AstraZeneca's oral drug camizestrant (brand name ETCAMAH). A companion diagnostic is a test doctors use before prescribing a drug to confirm it is the right treatment for a specific patient.
Guardant Health received European regulatory approval (CE-marking under IVDR) for its Guardant360 CDx blood test to be used as a companion diagnostic that identifies patients with a common type of advanced breast cancer who may benefit from AstraZeneca's oral drug camizestrant.
Guardant Health announced that results from the COSMOS-MEL01 study were published in Cancer Research Communications, an American Association for Cancer Research journal. The study is the first to prospectively evaluate, across multiple hospitals, the company's Guardant Reveal blood test for detecting remaining cancer (called molecular residual disease) and monitoring recurrence in melanoma patients.
Guardant Health announced that results from its COSMOS-MEL01 study were published in Cancer Research Communications, a journal of the American Association for Cancer Research. The study is the first published prospective, multicenter evaluation of the Guardant Reveal blood test for detecting molecular residual disease (MRD), meaning tiny traces of cancer left after treatment, and monitoring recurrence in melanoma patients.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| THC | Tenet Healthcare Corp | B | $22.15B | 9.90 | 1.23 | Compare |
| STE | STERIS plc | A- | $21.87B | 27.15 | 0.88 | Compare |
| LH | Labcorp Holdings Inc | A- | $26.36B | 26.30 | 0.89 | Compare |
| DGX | Quest Diagnostics Inc | A- | $26.40B | 24.67 | 0.56 | Compare |
| ALC | Alcon AG | B+ | $26.67B | 39.24 | 1.10 | Compare |
| ZBH | Zimmer Biomet Holdings, Inc | B+ | $18.37B | 22.28 | 0.49 | Compare |
| GEHC | GE Healthcare Technologies Inc | B | $31.78B | 16.01 | 0.84 | Compare |
| DXCM | Dexcom Inc | B | $33.10B | 32.73 | 1.44 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.